Emmanuel Gabriel1, Kristopher Attwood2, Rupen Shah1, Steven Nurkin1, Steven Hochwald1, Moshim Kukar3. 1. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY. 2. Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY. 3. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: moshim.kukar@roswellpark.org.
Abstract
BACKGROUND: Our group reported that patients with clinically node-negative esophageal adenocarcinoma do not derive overall survival (OS) benefit from neoadjuvant chemoradiation (nCRT) compared with clinically node-positive patients. The aim of this study was to develop a calculator that could more easily identify which patients derive OS benefit from nCRT. STUDY DESIGN: Using the National Cancer Data Base (2006 to 2012), patients with clinical status T1b to T4a, N-/+, M0 adenocarcinoma of the esophagus who underwent resection were selected. Of this cohort, 80% were randomly selected to develop and test the prediction model using Cox regression. The remaining 20% were used to internally validate the model, and performance was evaluated using receiver operating characteristic curves and area under the curves. RESULTS: A total of 8,974 patients met study criteria. Using the model testing cohort (7,179 patients), variables that were independently associated with OS in multivariable analysis were included in the model. These variables included Charlson-Deyo comorbidity score, tumor grade, clinical T and N status, and nCRT before surgery. Factors associated with increased risk of death were higher grade and higher T or N status. Receipt of nCRT was associated with improved OS. After validation, model performance showed an area under the curve of 0.630 and 0.682 for 1-year and 3-year OS, respectively. CONCLUSIONS: A novel OS calculator was developed for esophageal adenocarcinoma that reasonably predicts which patients are expected to derive OS benefit from nCRT. This tool can be helpful in determining OS benefit from nCRT to assist with treatment decision making.
BACKGROUND: Our group reported that patients with clinically node-negative esophageal adenocarcinoma do not derive overall survival (OS) benefit from neoadjuvant chemoradiation (nCRT) compared with clinically node-positive patients. The aim of this study was to develop a calculator that could more easily identify which patients derive OS benefit from nCRT. STUDY DESIGN: Using the National Cancer Data Base (2006 to 2012), patients with clinical status T1b to T4a, N-/+, M0 adenocarcinoma of the esophagus who underwent resection were selected. Of this cohort, 80% were randomly selected to develop and test the prediction model using Cox regression. The remaining 20% were used to internally validate the model, and performance was evaluated using receiver operating characteristic curves and area under the curves. RESULTS: A total of 8,974 patients met study criteria. Using the model testing cohort (7,179 patients), variables that were independently associated with OS in multivariable analysis were included in the model. These variables included Charlson-Deyo comorbidity score, tumor grade, clinical T and N status, and nCRT before surgery. Factors associated with increased risk of death were higher grade and higher T or N status. Receipt of nCRT was associated with improved OS. After validation, model performance showed an area under the curve of 0.630 and 0.682 for 1-year and 3-year OS, respectively. CONCLUSIONS: A novel OS calculator was developed for esophageal adenocarcinoma that reasonably predicts which patients are expected to derive OS benefit from nCRT. This tool can be helpful in determining OS benefit from nCRT to assist with treatment decision making.
Authors: Richard L Schilsky; Donna Bertucci; Nicholas J Vogelzang; Hedy L Kindler; Mark J Ratain Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Stephen G Swisher; Wayne Hofstetter; Tsung T Wu; Arlene M Correa; Jaffer A Ajani; Ritsuko R Komaki; Lucian Chirieac; Kelly K Hunt; Zhongxing Liao; Alexandria Phan; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg Journal: J Clin Oncol Date: 2005-03-21 Impact factor: 44.544
Authors: Robert Eil; Brian S Diggs; Samuel J Wang; James P Dolan; John G Hunter; Charles R Thomas Journal: Cancer Date: 2013-11-05 Impact factor: 6.860
Authors: Emmanuel Gabriel; Kristopher Attwood; William Du; Rebecca Tuttle; Raed M Alnaji; Steven Nurkin; Usha Malhotra; Steven N Hochwald; Moshim Kukar Journal: JAMA Surg Date: 2016-03 Impact factor: 14.766
Authors: Guillaume S Chevrollier; Danica N Giugliano; Francesco Palazzo; Scott W Keith; Ernest L Rosato; Nathaniel R Evans Iii; Adam C Berger Journal: J Gastrointest Surg Date: 2019-02-26 Impact factor: 3.452
Authors: H G van den Boorn; E G Engelhardt; J van Kleef; M A G Sprangers; M G H van Oijen; A Abu-Hanna; A H Zwinderman; V M H Coupé; H W M van Laarhoven Journal: PLoS One Date: 2018-02-08 Impact factor: 3.240
Authors: Emmanuel Gabriel; Jin Kim; Katherine T Ostapoff; Kristopher Attwood; Sergei Kurenov; Boris Kuvshinoff; Steven N Hochwald; Steven J Nurkin Journal: J Gastrointest Oncol Date: 2018-04
Authors: Ayesha Noorani; Xiaodun Li; Martin Goddard; Jason Crawte; Ludmil B Alexandrov; Maria Secrier; Matthew D Eldridge; Lawrence Bower; Jamie Weaver; Pierre Lao-Sirieix; Inigo Martincorena; Irene Debiram-Beecham; Nicola Grehan; Shona MacRae; Shalini Malhotra; Ahmad Miremadi; Tabitha Thomas; Sarah Galbraith; Lorraine Petersen; Stephen D Preston; David Gilligan; Andrew Hindmarsh; Richard H Hardwick; Michael R Stratton; David C Wedge; Rebecca C Fitzgerald Journal: Nat Genet Date: 2020-01-06 Impact factor: 38.330